Call for Papers  

Article Details

Review Article

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches

[ Vol. 28 , Issue. 11 ]


Martin K.R. Svačina and Helmar C. Lehmann*   Pages 854 - 862 ( 9 )


Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated polyradiculoneuropathy leading to disability via inflammatory demyelination of peripheral nerves. Various therapeutic approaches with different mechanisms of action are established for the treatment of CIDP. Of those, corticosteroids, intravenous or subcutaneous immunoglobulin, or plasma exchange are established first-line therapies as suggested by the recently revised EAN/PNS guidelines for the management of CIDP. In special cases, immunosuppressants or rituximab may be used. Novel therapeutic approaches currently undergoing clinical studies include molecules or monoclonal antibodies interacting with Fc receptors on immune cells to alleviate immune-mediated neuronal damage. Despite various established therapies and the current development of novel therapeutics, treatment of CIDP remains challenging due to an heterogeneous disease course and the lack of surrogate parameters to predict the risk of clinical deterioration. This review summarizes established therapies for CIDP and provides an outlook on future therapeutic approaches.


Chronic inflammatory demyelinating polyneuropathy, immune neuropathies, pharmacotherapy, novel therapies, intravenous immunoglobulin, plasma exchange, immunosuppressants, Fc receptor modulators.


Read Full-Text article